Next Article in Journal
Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression
Next Article in Special Issue
Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience
Previous Article in Journal
Analysis of Immunization, Adverse Events, and Efficacy of a Fourth Dose of BNT162b2 Vaccine in Health Workers in Mexico, a Pilot Study
Previous Article in Special Issue
Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19
 
 
Article

Article Versions Notes

Vaccines 2022, 10(7), 1140; https://doi.org/10.3390/vaccines10071140
Action Date Notes Link
article xml file uploaded 18 July 2022 11:38 CEST Original file -
article xml uploaded. 18 July 2022 11:38 CEST Update https://www.mdpi.com/2076-393X/10/7/1140/xml
article pdf uploaded. 18 July 2022 11:38 CEST Version of Record https://www.mdpi.com/2076-393X/10/7/1140/pdf
article html file updated 18 July 2022 11:40 CEST Original file -
article html file updated 13 August 2022 02:17 CEST Update https://www.mdpi.com/2076-393X/10/7/1140/html
Back to TopTop